Key result
Dipyridamole plus aspirin started before coronary artery bypass surgery markedly reduced vein-graft occlusion compared with placebo at a median of 1 year after operation.
Why the study?
Does platelet-inhibitor therapy initiated before coronary artery bypass surgery or coronary angioplasty reduce graft occlusion and restenosis?
Does platelet-inhibitor therapy initiated before coronary artery bypass surgery or coronary angioplasty reduce graft occlusion and restenosis?
Initiation of platelet-inhibitor therapy before coronary artery bypass surgery reduces vein-graft occlusion, while its efficacy before coronary angioplasty requires further clinical trials.
Answers are grounded in this paper and cite their sources.
May support pre-CABG dipyridamole-aspirin to reduce graft occlusion; leaves open efficacy before angioplasty.
The pathogenesis of aortocoronary vein-graft occlusion appears to be similar to the development of atherosclerosis, except that it is more accelerated, especially during the first postoperative year. Initiation of platelet-inhibitor therapy before operation is important especially in patients at high risk of bypass graft occlusion because platelet deposition starts during operation and initiates the process of occlusion. The largest and only placebo-controlled trial to start therapy before operation showed that dipyridamole (Persantine) plus aspirin markedly reduced occlusion (compared with placebo) in both high- and low-risk subgroups both early and at a median of 1 year after operation. Arterial balloon angioplasty often causes severe arterial wall injury, which is a potent stimulus for immediate platelet-thrombus deposition and is probably the main contributing factor in the process of restenosis. Animal studies suggest the potential value of antithrombotic therapy starting the day before the angioplasty procedure, but results from placebo-controlled trials in humans are needed before optimal therapy can be established.
No takes yet. Share an insight, caveat, or question.
Chesebro et al. (2008) conducted a review in Aortocoronary vein-graft occlusion and restenosis after coronary angioplasty. Platelet-inhibitor therapy (dipyridamole plus aspirin) vs. Placebo was evaluated on Vein-graft occlusion. Dipyridamole plus aspirin started before coronary artery bypass surgery markedly reduced vein-graft occlusion compared with placebo at a median of 1 year after operation.
Synapse has enriched 10 related papers. Consider them for comparative context: